- Liz Highleyman | 23 April 2015
Direct-acting antiviral regimens containing
sofosbuvir (Sovaldi) and the drugs in
Viekirax/Exviera were highly
effective regardless of how soon hepatitis C viral load became undetectable
after starting treatment, according to research presented at the recent ...
- Liz Highleyman | 22 April 2015
HIV-negative African women assigned to take once-daily
Truvada for HIV pre-exposure
prophylaxis (PrEP) achieved better adherence than those assigned to take PrEP
twice weekly or before and after sex, according to findings from ...
- Liz Highleyman | 13 April 2015
A combination regimen containing high-dose rifampicin (also known as
rifampin) was associated with faster tuberculosis (TB) bacteria culture
conversion in people with drug-sensitive TB, but moxifloxacin and the
experimental drug SQ109 showed no ...
- Liz Highleyman | 07 April 2015
People with HIV and hepatitis B or C virus co-infection are more likely
to progress to end-stage liver disease (ESLD), or liver failure, than those
with HIV alone, and individuals triply infected ...
- Liz Highleyman | 31 March 2015
In addition to the
usual risk factors for hepatitis C virus (HCV) sexual transmission seen in most
previous studies – such as anal sex and having other sexually transmitted
infections – researchers in ...
- Liz Highleyman | 24 March 2015
Researchers at the recent Conference on Retroviruses and Opportunistic
Infections (CROI 2015) in Seattle, USA, presented data on several
experimental agents that may play a role in achieving a 'functional cure' for
HIV, or ...
- Liz Highleyman | 24 March 2015
Starting antiretroviral therapy (ART) very soon after
infection may limit the size of the HIV 'reservoir' and
delay viral rebound after treatment interruption, according to several
presentations at the recent Conference on
Retroviruses and ...
- Liz Highleyman | 19 March 2015
An combination of two once-daily oral antiretrovirals –
the next-generation integrase inhibitor cabotegravir (GSK1265744) and the
approved NNRTI rilpivirine (Edurant, also in Eviplera
or Complera) – was as effective as an efavirenz (Sustiva)-based regimen ...
- Theo Smart | 18 March 2015
The Fracture Risk Assessment Tool (FRAX), an online
tool developed by the World Health Organization and used to help guide
decisions about who to screen or treat in order to prevent bone ...
- Liz Highleyman | 17 March 2015
Almost all patients
with hepatitis C virus (HCV) alone or HIV and HCV co-infection who achieved sustained
virological response (SVR) to treatment with sofosbuvir (Sovaldi) plus ribavirin or sofosbuvir/ledipasvir (Harvoni) still had ...
- Liz Highleyman | 16 March 2015
Inflammatory changes and damage to the gut begin very soon after initial
HIV infection, and may not return to normal even when people start
antiretroviral therapy (ART) very early, researchers reported at ...
- Theo Smart | 12 March 2015
Existing algorithms to screen for anal cancer in women
living with HIV could be missing many cases of anal high-grade squamous
intraepithelial lesions (HSIL) – abnormal tissue changes that may be a ...
- Michael Carter | 11 March 2015
Rates of hepatitis
C virus (HCV) reoccurrence after successful therapy differ markedly between
risk groups, according to the results of a meta-analysis presented at the
recent Conference on Retroviruses and Opportunistic Infections (CROI ...
- Liz Highleyman | 10 March 2015
People with HIV and hepatitis C virus (HCV) co-infection who take sofosbuvir/ledipasvir (Harvoni)
to treat hepatitis C along with boosted protease inhibitor antiretroviral
regimens may experience changes in drugs levels, but these ...
- Theo Smart | 10 March 2015
Evidence is mounting
that statin therapy can prevent the progression of coronary atherosclerosis
(hardening and narrowing of the arteries supplying the heart) in people living
with HIV, according to the results of two ...
- Gus Cairns | 09 March 2015
It is unlikely that one single approach will achieve a cure
for HIV infection, delegates at a community cure workshop held the day before
the Conference on Retroviruses and Opportunistic Infections (CROI ...
- Gus Cairns | 06 March 2015
HIV infection, or inflammatory changes associated with it, may
be responsible for fat accumulation and body fat redistribution, rather than
HIV drugs, the Conference on Retroviruses and Opportunistic Infections (CROI 2015) in ...
- Theo Smart | 05 March 2015
Using low-dose computed tomography to screen selected people living with
HIV who smoke, led to early lung cancer diagnoses at younger ages than normally
seen in the general population, according to findings ...
- Theo Smart | 04 March 2015
Smoking appears to contribute
most to the burden of non-AIDS-defining cancers diagnosed in people living with
HIV in the US, out of all the potential modifiable risk factors – including
hepatitis B or ...
- Liz Highleyman | 04 March 2015
The smoking cessation drug varenicline (Champix,
or Chantix in the United States) helped more people with
HIV to stop smoking than counselling alone, but less than 20% were able to remain
abstinent for ...